A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease
详细信息 查看全文
- 作者：Pooja Khandelwal ; Pooja.khandelwal@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; Jacob J. Bleesing ; Stella M. Davies ; Rebecca A. Marsh
- 关键词：CGD ; Chronic granulomatous disease ; Reduced-intensity conditioning regimen for CGD
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：22
- 期：11
- 页码：2011-2018
- 全文大小：1011 K
文摘
- •
Alemtuzumab, fludarabine, and melphalan have high rates of mixed chimerism in CGD but low toxicity.
- •
Busulfan, cyclophosphamide, and ATG are associated with >90% myeloid chimerism but high rates of toxicity.
- •
A lower targeted busulfan approach leads to acceptable myeloid chimerism and low toxicity in CGD.